Werner Sean, CTO, reported a transaction classified as grant at BIOLIFE SOLUTIONS INC involving 45838.000000 shares. Reported holdings after the transaction were 47033.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
Chief Technology Officer
Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger S…
The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the re…
The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effect…
Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
0 other filings
0 recent txs